Total-SMAD2 cellular kit HTRF®

The Total-SMAD2 assay quantifies the expression level of SMAD2 in a cell lysate. Unlike Western Blot, the assay is entirely plate-based and does not require gels, electrophoresis, or transfer.

The Total-SMAD2 assay uses two labeled antibodies: one coupled to a donor fluorophore, the other to an acceptor. Both antibodies are highly specific for a distinct epitope on the protein. In presence of SMAD2 in a cell extract, the addition of these conjugates brings the donor fluorophore into close proximity with the acceptor and thereby generates a FRET signal. Its intensity is directly proportional to the concentration of the protein present in the sample, and provides a means of assessing the protein’s expression under a no-wash assay format.

The 2 plate protocol involves culturing cells in a 96-well plate before lysis, then transferring lysates to a 384-well low volume detection plate before adding Total-SMAD2 HTRF detection reagents.

This protocol enables the cells' viability and confluence to be monitored.

Detection of total SMAD2 with HTRF reagents can be performed in a single plate used for culturing, stimulation, and lysis. No washing steps are required.

This HTS designed protocol enables miniaturization while maintaining robust HTRF quality.

C2C12 cells were plated at 50,000 cells per well in a 96-well plate. After an overnight incubation at 37°C, 5% CO2, a serial dilution of human TGFβ was added to the cells for 30 minutes at 37°C, 5% CO2. Stimulation medium was removed, and 50µL of lysis buffer was added to the cells. A lysis step was carried out, shaking gently for 30 minutes. 16µL of samples were transferred into a 384-well small volume plate, then 4µL of Phospho-SMAD2 HTRF detection reagents were added. In parallel, 16µl of samples were dispensed into other wells, then 4µL of Total-SMAD2 HTRF detection reagents were added. Signals were recorded overnight.

Hela cells were selected for testing human compatibility, while NIH 3T3 and C2C12 cells were chosen for mouse compatibility. 100,000 cells of these different models were plated in 96-well plates. After an overnight incubation at 37°C, 5% CO2, cell culture medium was removed and 50µL of lysis buffer were added to the cells. A lysis step was carried out, shaking  gently for 30 minutes. 16µL of samples were transferred into a 384-well small volume plate, then 4µL of Total-SMAD2 HTRF detection reagents were added. Signals were recorded overnight.

The Total-SMAD2 HTRF assay was able to detect human and mouse SMAD2 proteins.

Mouse C2C12 cells were cultured to 80% confluency. After hTGFβ treatment, cells were lysed and soluble supernatants were collected via centrifugation. Serial dilutions of the cell lysate were performed, and 16 µL of each dilution were transferred into a 384-well low volume white microplate before finally adding Total-SMAD2 cellular kit reagents. A side by side comparison showed the HTRF Total assay is at least 9-fold more sensitive than the Western Blot.

​TGF-ß signaling is mediated by complexes of TßRI and TßRII, which activate intracellular SMAD3 and SMAD2 by phosphorylation. The binding of the TGF-ß ligand on TßRII triggers the recruitment of TßRI into the ligand-receptor complex. TßRII autophosphorylates, then transphosphorylates TßRI. Activated TßRI in turn phosphorylates SMAD2 on Ser465 and Ser467, enabling its oligomerization with SMAD4.

This complex then translocates to the nucleus. There, it acts as a transcription factor with coactivators and corepressors to regulate the expression of multiple genes involved in cell growth, apoptosis, proliferation, migration, and differentiation, as well as in extracellular matrix remodeling and immune/inflammatory responses. Inhibitory SMAD6 and SMAD7 are involved in feedback inhibition of the pathway.